Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.
Read more …New immune boost could expand access to cancer immunotherapy
A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also carry such variants do not. The prevailing theory has suggested additional genetic factors may play a role. To address this question, a new study used modern technology, called CRISPR interference, to systematically examine every gene in the human genome. The scientists identified a new set of genes that contribute to the risk of Parkinson's disease, which opens the door to previously untapped drug targets for treating PD.
Read more …New key genes in Parkinson's disease identified using CRISPR technology
A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team identified a monoclonal antibody called KG2032 that reacts with a certain variant of the HLA-DRB1 molecule. KG2032 CAR T cells displayed strong anti-AML effects in a mouse model, and CAR natural killer cells showed similar results. Clinical trials are currently being planned.
Read more …Driving the CAR to fight acute myeloid leukemia